Drug Delivery of siRNA Therapeutics

The new frontier of pharmaceutical sciences is gene therapy, which is the use of molecules able to interact directly with the expression of the genetic material of the patient as well as of the disease-causing guest (bacteria, virus, parasites, and tumor cells). Among the molecules of interest for g...

Full description

Saved in:
Bibliographic Details
HerausgeberIn:
Sonstige:
Year of Publication:2020
Language:English
Physical Description:1 electronic resource (288 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 04041nam-a2201093z--4500
001 993545996204498
005 20231214133211.0
006 m o d
007 cr|mn|---annan
008 202105s2020 xx |||||o ||| 0|eng d
035 |a (CKB)5400000000042842 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/68603 
035 |a (EXLCZ)995400000000042842 
041 0 |a eng 
100 1 |a Lamberti, Gaetano  |4 edt 
245 1 0 |a Drug Delivery of siRNA Therapeutics 
260 |a Basel, Switzerland  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2020 
300 |a 1 electronic resource (288 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
520 |a The new frontier of pharmaceutical sciences is gene therapy, which is the use of molecules able to interact directly with the expression of the genetic material of the patient as well as of the disease-causing guest (bacteria, virus, parasites, and tumor cells). Among the molecules of interest for gene therapy, a relevant role is played by small interfering RNA (siRNA) molecules able to interfere with the expression of genes of interest for some diseases. However, siRNA molecules, even if they are powerful as drugs, are difficult to deliver since they are sensitive to enzymes present in plasma and they are large and negatively charged, so are difficult to administer into the cell nuclei, since the cell walls are scarcely permeable to large molecules and are also negatively charged. Therefore, the focus of research on siRNA-based therapies is their delivery, which can be performed by chemical modification, association with aptamers or polycations, or embedding them into properly designed liposomes. This book is centered on the more recent development in siRNA delivery techniques toward the clinical applications of this potent class of drugs. 
546 |a English 
650 7 |a Medicine  |2 bicssc 
653 |a oligonucleotide delivery 
653 |a light-activated release 
653 |a intracellular release 
653 |a liposome 
653 |a indocyanine green 
653 |a drug co-delivery 
653 |a methotrexate 
653 |a siRNA 
653 |a antitumor effect 
653 |a mixed micelles 
653 |a targeted delivery system 
653 |a cationic liposome 
653 |a folate 
653 |a folate receptor 
653 |a cationic cholesterol derivative 
653 |a siRNA delivery 
653 |a gene knockdown 
653 |a tumor-targeting 
653 |a VEGFA 
653 |a VEGFR1 
653 |a endoglin 
653 |a peptide 
653 |a angiogenesis 
653 |a gene silencing 
653 |a migration 
653 |a proliferation 
653 |a endothelial cells 
653 |a RNAi therapeutics 
653 |a amphiphilic dendrons 
653 |a PAMAM dendrimers 
653 |a self-assembling 
653 |a nanovectors 
653 |a covalent dendrimers 
653 |a NABDs 
653 |a liposomes 
653 |a clinical trials 
653 |a drug delivery 
653 |a nanoparticle 
653 |a carbonate apatite 
653 |a ERBB2 
653 |a AKT 
653 |a breast cancer 
653 |a ovarian cancer 
653 |a polymer 
653 |a lipid 
653 |a delivery 
653 |a poly(ethylene) imine 
653 |a PEI 
653 |a RNA 
653 |a tyrosine-modification 
653 |a tumor xenograft 
653 |a magnetic nanoparticle 
653 |a iron oxide 
653 |a BCL2 
653 |a BIRC5/survivin 
653 |a oral cancer 
653 |a aptamers 
653 |a cancer 
653 |a nanoparticles 
653 |a STAT6 
653 |a polyaspartamide 
653 |a pegylation 
653 |a polyamine 
653 |a polyplexes 
653 |a asthma 
776 |z 3-03936-200-3 
776 |z 3-03936-201-1 
700 1 |a Angela Barba, Anna  |4 edt 
700 1 |a Lamberti, Gaetano  |4 oth 
700 1 |a Angela Barba, Anna  |4 oth 
906 |a BOOK 
ADM |b 2023-12-15 05:46:32 Europe/Vienna  |f system  |c marc21  |a 2022-04-04 09:22:53 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338061420004498&Force_direct=true  |Z 5338061420004498  |b Available  |8 5338061420004498